Update on Hodgkin Lymphoma – July 17, 2024
Featuring: Dr. Jamie Flerlage, Wilmot Cancer Institute, University of Rochester
Category Hodgkin Lymphoma
Harsh Shah, DO
Researcher Spotlight: Harsh Shah, DO THE UNIVERSITY OF UTAHStedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused on…
Brian Sworder, MD, PhD
Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphoma who have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse…
Patrizia Mondello, MD, PhD
Researcher Spotlight: Patrizia Mondello, MD, PhD Mayo Clinic, Rochester Follicular lymphoma (FL) is generally slow-growing cancer with an overall favorable prognosis. One subset, known as FL3B, has a distinctly worse clinical outcome with limited treatment options. The same treatments used to manage…
Tomohiro Aoki, PhD
Researcher Spotlight: Tomohiro Aoki, PhD British Columbia Cancer Research Centre Hodgkin lymphoma (HL) treatment relies on multimodality treatment with standard chemotherapy, radiation therapy, and autologous or allogeneic stem cell transplantation in cases of relapsed disease. For his LRF research project, Dr. Tomohiro…
Erin Mulvey, MD
Researcher Spotlight: Erin Mulvey, MD Weill Cornell Medical College Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common types of non-Hodgkin lymphoma, with one categorized as aggressive (fast-growing) and one considered indolent (slow-growing), respectively. First-line treatment…
Luis Malpica Castillo, MD
Researcher Spotlight: Luis Malpica Castillo, MD The University of Texas M.D. Anderson Cancer Center Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, generally incurable type of non-Hodgkin lymphoma (NHL) caused by infection with the human T-cell leukemia virus type 1 (HTLV-1).…
Arushi Khurana, M.B.B.S
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuse large B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over…
P. Connor Johnson, MD
Researcher Spotlight: P. Connor Johnson, MD Massachusetts General Hospital Older adults with fast-growing lymphomas are often treated with chemotherapy which has the potential to cure some of these diseases. However, understanding which patients will have serious side effects, complications, and…
Nicole Prutsch, PhD
Researcher Spotlight: Nicole Prutsch, PhD Dana-Farber Cancer Institute T-cell lymphomas represent a heterogeneous group of peripheral and cutaneous non-Hodgkin lymphomas (NHL) with a range of unmet clinical needs. Anaplastic large cell lymphoma (ALCL) is a CD30+ subtype of non-Hodgkin T-cell…